BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mühlbacher A, Bethge S. First and Foremost Battle the Virus: Eliciting Patient Preferences in Antiviral Therapy for Hepatitis C Using a Discrete Choice Experiment. Value Health 2016;19:776-87. [PMID: 27712705 DOI: 10.1016/j.jval.2016.04.007] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
Number Citing Articles
1 Reed SD, Lavezzari G. International Experiences in Quantitative Benefit-Risk Analysis to Support Regulatory Decisions. Value Health 2016;19:727-9. [PMID: 27712697 DOI: 10.1016/j.jval.2016.06.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
2 Adam D, Keller T, Mühlbacher A, Hinse M, Icke K, Teut M, Brinkhaus B, Reinhold T. The Value of Treatment Processes in Germany: A Discrete Choice Experiment on Patient Preferences in Complementary and Conventional Medicine. Patient 2019;12:349-60. [PMID: 30565073 DOI: 10.1007/s40271-018-0353-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
3 Jonker MF, Donkers B, de Bekker-Grob E, Stolk EA. Attribute level overlap (and color coding) can reduce task complexity, improve choice consistency, and decrease the dropout rate in discrete choice experiments. Health Econ 2019;28:350-63. [PMID: 30565338 DOI: 10.1002/hec.3846] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
4 Mühlbacher AC, Sadler A. The Probabilistic Efficiency Frontier: A Framework for Cost-Effectiveness Analysis in Germany Put into Practice for Hepatitis C Treatment Options. Value Health 2017;20:266-72. [PMID: 28237207 DOI: 10.1016/j.jval.2016.12.015] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 6.2] [Reference Citation Analysis]
5 Mühlbacher AC, Sadler A. Comment on the paper "Cost-effectiveness of sofosbuvir in hepatitis C genotype 1 infection in Germany: A reanalysis of published results". PLoS One 2021;16:e0245480. [PMID: 33600462 DOI: 10.1371/journal.pone.0245480] [Reference Citation Analysis]
6 Ver Donck N, Vander Stichele G, Huys I. Improving Patient Preference Elicitation by Applying Concepts From the Consumer Research Field: Narrative Literature Review. Interact J Med Res 2020;9:e13684. [PMID: 32229460 DOI: 10.2196/13684] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
7 Welzel TM, Yang M, Sajeev G, Chen YJ, Pinsky B, Bao Y, Wu EQ, Dieterich D. Assessing Patient Preferences for Treatment Decisions for New Direct Acting Antiviral (DAA) Therapies for Chronic Hepatitis C Virus Infections. Adv Ther 2019;36:2475-86. [PMID: 31240629 DOI: 10.1007/s12325-019-01012-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
8 Masri HE, McGuire TM, Dalais C, van Driel M, Benham H, Hollingworth SA. Patient-based benefit-risk assessment of medicines: development, refinement, and validation of a content search strategy to retrieve relevant studies. J Med Libr Assoc 2022;110:185-204. [PMID: 35440905 DOI: 10.5195/jmla.2022.1306] [Reference Citation Analysis]
9 Soekhai V, de Bekker-Grob EW, Ellis AR, Vass CM. Discrete Choice Experiments in Health Economics: Past, Present and Future. Pharmacoeconomics 2019;37:201-26. [PMID: 30392040 DOI: 10.1007/s40273-018-0734-2] [Cited by in Crossref: 140] [Cited by in F6Publishing: 126] [Article Influence: 70.0] [Reference Citation Analysis]
10 Shumway M, Luetkemeyer AF, Peters MG, Johnson MO, Napoles TM, Riley ED. Direct-acting antiviral treatment for HIV/HCV patients in safety net settings: patient and provider preferences. AIDS Care 2019;31:1340-7. [PMID: 30829533 DOI: 10.1080/09540121.2019.1587353] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
11 Jonker MF, Donkers B, de Bekker-Grob EW, Stolk EA. Effect of Level Overlap and Color Coding on Attribute Non-Attendance in Discrete Choice Experiments. Value Health 2018;21:767-71. [PMID: 30005748 DOI: 10.1016/j.jval.2017.10.002] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 5.0] [Reference Citation Analysis]
12 Mattingly TJ, Slejko JF, Perfetto EM, Kottilil S, Mullins CD. What Matters Most for Treatment Decisions in Hepatitis C: Effectiveness, Costs, and Altruism. Patient 2019;12:631-8. [DOI: 10.1007/s40271-019-00378-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
13 Hardtstock F, Sbarigia U, Kocaata Z, Wilke T, Sylvester SV. Preferences of Patients with Chronic Hepatitis B - A Discrete Choice Experiment on the Acceptability of Functional Cure. Patient Prefer Adherence 2020;14:613-24. [PMID: 32256052 DOI: 10.2147/PPA.S238833] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
14 Feldman TC, Dienstag JL, Mandl KD, Tseng YJ. Machine-learning-based predictions of direct-acting antiviral therapy duration for patients with hepatitis C. Int J Med Inform 2021;154:104562. [PMID: 34482150 DOI: 10.1016/j.ijmedinf.2021.104562] [Reference Citation Analysis]